The FDA on April 23, 2021 granted accelerated approval to ZYNLONTA®, a CD19-directed antibody and alkylating agent conjugate, for adult patients with Relapsed or Refractory Large B-Cell Lymphoma after two or more lines of systemic therapy, including Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified, DLBCL arising from Low Grade Lymphoma, and High-Grade B-cell Lymphoma. ZYNLONTA® is a product of ADC Therapeutics SA.
Bottom Ad
Advertisement
Subscribe
